Literature DB >> 17620381

In vivo activity of a novel polymeric guanidine in experimental skin infection with methicillin-resistant Staphylococcus aureus.

Christina Kratzer1, Selma Tobudic, Karin Macfelda, Wolfgang Graninger, Apostolos Georgopoulos.   

Abstract

The in vivo efficacy of the novel polymeric guanidine AKACID Plus was evaluated in a guinea pig model of experimental skin infection with methicillin-resistant Staphylococcus aureus (MRSA). Topical application of AKACID Plus at concentrations of > or =0.5% was as effective as mupirocin 2% cream in the treatment of superficial skin infection with MRSA.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17620381      PMCID： PMC2043190          DOI： 10.1128/AAC.00130-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Efficacy of a new cream formulation of mupirocin: comparison with oral and topical agents in experimental skin infections.

Authors:  J Gisby; J Bryant
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Validation of AKACID plus as a room disinfectant in the hospital setting.

Authors:  Christina Kratzer; Selma Tobudic; Ojan Assadian; Astrid Buxbaum; Wolfgang Graninger; Apostolos Georgopoulos
Journal:  Appl Environ Microbiol       Date:  2006-06       Impact factor: 4.792

3.  Antimicrobial and toxicological profile of the new biocide Akacid plus.

Authors:  Astrid Buxbaum; Christina Kratzer; Wolfgang Graninger; Apostolos Georgopoulos
Journal:  J Antimicrob Chemother       Date:  2006-06-02       Impact factor: 5.790

4.  Ultrastructural evidences of growth inhibitory effects of a novel biocide, Akacid(plus), on an aflatoxigenic Aspergillus parasiticus.

Authors:  Mehdi Razzaghi-Abyaneh; Masoomeh Shams-Ghahfarokhi; Masanobu Kawachi; Ali Eslamifar; Oskar J Schmidt; Andreas Schmidt; Abdolamir Allameh; Tomoya Yoshinari
Journal:  Toxicon       Date:  2006-09-10       Impact factor: 3.033

5.  Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods.

Authors:  L M Deshpande; A M Fix; M A Pfaller; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2002-04       Impact factor: 2.803

6.  Akacid-medical-formulation, a novel biocidal oligoguanidine with antitumor activity reduces S-phase in prostate cancer cell lines through the Erk 1/2 mitogen-activated protein kinase pathway.

Authors:  Hannes Neuwirt; Hansgeorg Muller; Ilaria T R Cavarretta; Martin Tiefenthaler; Georg Bartsch; Guenther Konwalinka; Zoran Culig
Journal:  Int J Oncol       Date:  2006-08       Impact factor: 5.650

7.  In vitro antimicrobial activity of the novel polymeric guanidine Akacid plus.

Authors:  C Kratzer; S Tobudic; W Graninger; A Buxbaum; A Georgopoulos
Journal:  J Hosp Infect       Date:  2006-05-15       Impact factor: 3.926

8.  Performance of a new chromogenic oxacillin resistance screen medium (Oxoid) in the detection and presumptive identification of methicillin-resistant Staphylococcus aureus.

Authors:  Petra Apfalter; Ojan Assadian; Andrea Kalczyk; Verena Lindenmann; Athanasios Makristathis; Stefan Mustafa; Manfred Rotter; Alexander M Hirschl
Journal:  Diagn Microbiol Infect Dis       Date:  2002-10       Impact factor: 2.803

9.  Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective?

Authors:  Elaine S Walker; Jose E Vasquez; Roy Dula; Hollie Bullock; Felix A Sarubbi
Journal:  Infect Control Hosp Epidemiol       Date:  2003-05       Impact factor: 3.254

10.  Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections.

Authors:  Trish M Perl; Joseph J Cullen; Richard P Wenzel; M Bridget Zimmerman; Michael A Pfaller; Deborah Sheppard; Jennifer Twombley; Pamela P French; Loreen A Herwaldt
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245
View more
  2 in total

1.  Akacid medical formulation induces apoptosis in myeloid and lymphatic leukemic cell lines in vitro and in vivo.

Authors:  Hannes Neuwirt; Elisabeth Wabnig; Clemens Feistritzer; Iris E Eder; Christina Salvador; Martin Puhr; Zoran Culig; Petra Massoner; Martin Tiefenthaler; Michael Steurer; Guenther Konwalinka
Journal:  PLoS One       Date:  2015-02-13       Impact factor: 3.240

2.  Mycobacterium ulcerans fails to infect through skin abrasions in a guinea pig infection model: implications for transmission.

Authors:  Heather R Williamson; Lydia Mosi; Robert Donnell; Maha Aqqad; Richard W Merritt; Pamela L C Small
Journal:  PLoS Negl Trop Dis       Date:  2014-04-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.